Michael D. Green

Michael D. Green, MD, PhD, serves as Assistant Professor in the Department of Radiation Oncology at the University of Michigan Medical School and Attending Physician at the Ann Arbor VA. His work bridges clinical radiation oncology with translational tumor immunology research, focusing on integrating immunotherapy into cancer treatment through quantitative immunophenotyping, image analysis, and lipidomics to advance radiobiology.

Dr. Green's educational background includes:

• Medical and graduate degrees from Icahn School of Medicine at Mount Sinai
• Residency in Radiation Oncology at University of Michigan (Chief Resident)
• Postdoctoral training in tumor immunology with Weiping Zou

The Green laboratory investigates molecular, metabolic, and cellular checkpoints influencing CD8+ T-cell function in tumor microenvironments, with emphasis on ferroptosis, hepatic immune tolerance, and therapy efficacy determinants. Their approach combines quantitative immunophenotyping, programmed cell death analysis, and oxidized lipidomics to develop novel cancer treatment strategies through clinical, translational, and preclinical studies.

Analysis of Dr. Green's 15 most recent publications (2021-2023) reveals dominant themes in lung/colorectal cancer biomarker discovery (PD-L1, neutrophil-to-lymphocyte ratio), immune resistance mechanisms (T-cell exhaustion, tissue-specific Tregs), and ferroptosis-lipid oxidation roles in radiotherapy enhancement. Over 60% of recent work examines durvalumab applications in stage III NSCLC and liver-immunity interactions in metastasis.

No scientific awards were mentioned in the provided text.

Dr. Green advises two Immunology Program graduate students (Ashley Pearson, Erin Holcomb) on projects involving ferroptosis, hepatic immune tolerance, and immunotherapy-radiotherapy efficacy determinants. His research receives grant support for clinical-translational studies developing combination cancer therapies through VA and university collaborations.

The Green laboratory operates within University of Michigan's radiation oncology-immunology ecosystem with VA resources, focusing on quantitative tumor microenvironment analysis. Current initiatives include real-time anticancer therapy surveillance in veterans, blood biomarker protocols, and precision immunotherapy targeting tissue-specific immune checkpoints.